miglustat has been researched along with Cognition Disorders in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caciotti, A; Deodato, F; Dionisi-Vici, C; Donati, MA; Morrone, A; Procopio, E; Rampazzo, A; Scarpa, M; Taurisano, R | 1 |
| Döme, P; Faludi, G; Gonda, X | 1 |
| Cuisset, JM; Dobbelaere, D; Latour, P; Michaud, L; Sukno, S; Trauffler, A; Vallée, L | 1 |
| Sedel, F | 1 |
| Antebi, V; Arnon, Y; Doniger, GM; Elstein, D; Guedalia, J; Simon, ES; Zimran, A | 1 |
2 review(s) available for miglustat and Cognition Disorders
| Article | Year |
|---|---|
[Adult psychiatric aspects of Niemann-Pick disease].
Topics: 1-Deoxynojirimycin; Age of Onset; Cataplexy; Cognition Disorders; Enzyme Inhibitors; Humans; Niemann-Pick Disease, Type A; Niemann-Pick Disease, Type B; Niemann-Pick Disease, Type C; Niemann-Pick Diseases; Sphingolipids; Sphingomyelin Phosphodiesterase | 2013 |
[Clinical diagnosis of the adult form of Niemann-Pick type C disease].
Topics: 1-Deoxynojirimycin; Adult; Cerebellar Ataxia; Cognition Disorders; Deglutition Disorders; Dysarthria; Enzyme Inhibitors; Epilepsy; Humans; Mental Disorders; Movement Disorders; Niemann-Pick Disease, Type C; Splenomegaly; Supranuclear Palsy, Progressive | 2010 |
1 trial(s) available for miglustat and Cognition Disorders
| Article | Year |
|---|---|
Computerized cognitive testing in patients with type I Gaucher disease: effects of enzyme replacement and substrate reduction.
Topics: 1-Deoxynojirimycin; Adult; Aged; Cognition Disorders; Enzyme Inhibitors; Female; Gaucher Disease; Humans; Intelligence Tests; Male; Middle Aged; Neuropsychological Tests; Observer Variation; Psychometrics; Reproducibility of Results; User-Computer Interface | 2005 |
2 other study(ies) available for miglustat and Cognition Disorders
| Article | Year |
|---|---|
The treatment of juvenile/adult GM1-gangliosidosis with Miglustat may reverse disease progression.
Topics: 1-Deoxynojirimycin; Adult; Age Factors; beta-Galactosidase; Cognition Disorders; Disease Progression; Female; Follow-Up Studies; Gait; Gangliosidosis, GM1; Genotype; Glycoside Hydrolase Inhibitors; Humans; Language Disorders; Motor Skills; Movement Disorders; Neuropsychological Tests; Treatment Outcome; Walking; Young Adult | 2017 |
Impact of miglustat on evolution of atypical presentation of late-infantile-onset Niemann-Pick disease type C with early cognitive impairment, behavioral dysfunction, epilepsy, ophthalmoplegia, and cerebellar involvement: a case report.
Topics: 1-Deoxynojirimycin; Adolescent; Carrier Proteins; Cerebellum; Cognition Disorders; Enzyme Inhibitors; Epilepsy; Humans; Intracellular Signaling Peptides and Proteins; Magnetic Resonance Imaging; Male; Membrane Glycoproteins; Mental Disorders; Mutation; Niemann-Pick C1 Protein; Niemann-Pick Disease, Type C; Ophthalmoplegia; Treatment Outcome | 2016 |